Financial reports
10-K
2023 FY
Annual report
26 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
26 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K/A
2022 FY
Annual report (amended)
28 Apr 23
10-K
2022 FY
Annual report
17 Apr 23
NT 10-K
Notice of late annual filing
31 Mar 23
10-Q
2022 Q3
Quarterly report
18 Nov 22
NT 10-Q
Notice of late quarterly filing
14 Nov 22
Current reports
8-K
Entry into a Material Definitive Agreement
18 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Apr 24
8-K
Augmedix Delivers 45% Revenue Growth and Expanded Gross Margins for Fourth Quarter of 2023
18 Mar 24
8-K
Entry into a Material Definitive Agreement
9 Jan 24
8-K
Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue
5 Jan 24
8-K
Entry into a Material Definitive Agreement
29 Nov 23
8-K
Augmedix Announces Closing of Public Offering of Common Stock, Including Additional Investments from HCA Healthcare
21 Nov 23
8-K
Augmedix Announces Proposed Public Offering of 5,500,000 Shares of Common Stock
20 Nov 23
8-K
Other Events
15 Nov 23
8-K
Augmedix Delivers 50% Revenue Growth and Expanded Gross Margins for Third Quarter of 2023
6 Nov 23
Registration and prospectus
S-8
Registration of securities for employees
27 Mar 24
424B5
Prospectus supplement for primary offering
17 Nov 23
424B5
Prospectus supplement for primary offering
15 Nov 23
S-8
Registration of securities for employees
12 Jun 23
S-3
Shelf registration
19 May 23
D
$12.00 mm in equity / options, sold $12.00 mm, 2 investors
2 May 23
POS AM
Prospectus update (post-effective amendment)
27 Jul 22
RW
Registration withdrawal request
27 Jul 22
S-8
Registration of securities for employees
22 Jul 22
S-3
Shelf registration
22 Jul 22
Other
EFFECT
Notice of effectiveness
30 May 23
CORRESP
Correspondence with SEC
24 May 23
UPLOAD
Letter from SEC
22 May 23
EFFECT
Notice of effectiveness
9 Aug 22
EFFECT
Notice of effectiveness
6 May 22
CORRESP
Correspondence with SEC
3 May 22
UPLOAD
Letter from SEC
22 Apr 22
EFFECT
Notice of effectiveness
8 Oct 21
CERT
Certification of approval for exchange listing
7 Oct 21
CORRESP
Correspondence with SEC
5 Oct 21